Forlax powder for solution for oral administration in bags 10g №20

Name:
Forlax. Release form Powder for solution for oral administration. Dosage 10 g. Pack quantity: 20 pcs. Produced by Bofur Ipsen Industry. INN Macrogol FTGS Laxative. Composition Each package contains: Active ingredient: Macrogol 4000 10.00 g Auxiliary components: Sodium saccharin (E954) 0.017 g Orange-grapefruit flavor * 0.15 g * Orange-grapefruit flavor contains orange and grapefruit oils, concentrated orange juice, citral, acetaldehyde, linalol, ethyl butyrate, alpha terpineol, octanol, beta gamma hexenol, maltodextrin, gum arabic, BHA (butylhydroxyanisole, E320), and also: Sorbitol (E420) 1.8 mg Sulfur dioxide (E220) 0.24 * 10- 2 mg
Description:
White or almost white powder with orange and grapefruit odor, highly soluble in water. Pharmacotherapeutic group Osmotically acting laxatives ATC code: A06AD15 High molecular weight (4000) macrogols are long linear polymers that hold water molecules through hydrogen bonds. When taken orally, they increase the volume of fluid contained in the intestines. The laxative properties of the solution are explained by the volume of non-absorbable fluid in the intestine. Pharmacokinetic characteristics Pharmacokinetic data confirm the absence of intestinal absorption and biotransformation of macrogol 4000 after oral administration. Indications for use Symptomatic treatment of constipation in adults and children over 8 years of age. Before proceeding with treatment, it is necessary to exclude the organic cause of the disorder. Treatment of constipation in children should not be long and exceed 3 months, combined with observance of general hygiene measures and diet therapy until complete restoration of transit. If symptoms persist despite hygienic and dietary measures, the appropriate cause of constipation should be identified and treated. Contraindications • Severe inflammatory bowel disease (diseases such as ulcerative colitis, Crohn’s disease) or toxic megacolon. • intestinal perforation or risk of perforation, • intestinal obstruction or suspected intestinal obstruction, symptomatic stenosis, • abdominal pain syndrome of unknown etiology, • hypersensitivity to the active substance or to any of the auxiliary components. Dosing and Administration Oral administration. The contents of each sachet must be dissolved in a glass of water immediately before taking. Method of application The daily dose is 1-2 sachets (10-20 g), it is recommended to take it in one dose in the morning. The daily dose may vary according to the clinical effect and range from one sachet (especially in children) to 2 sachets per day. The action of Forlax appears within 24-48 hours after administration. If the drug was missed, it is necessary to take the drug at the usual dose, do not double the dose to compensate for the missed one. Use in children The duration of treatment in children should not exceed 3 months, given the lack of clinical data on taking the drug for a longer period. Improving the passage through the intestines under the influence of the ongoing treatment should be supported by general hygiene measures and diet therapy. How to use The contents of each sachet must be dissolved in a glass of water immediately before taking. PrecautionsPrevention Drug treatment of constipation should only be considered as an adjunct to the following general hygiene measures and dietary therapy: • additional intake of food rich in plant fibers and sufficient fluids; • a physically active lifestyle and restoration of defecation reflexes. An organic disorder must be ruled out before starting treatment. This drug contains macrogol (polyethylene glycol). There are reports of cases of hypersensitivity (anaphylactic shock, angioedema, urticaria, rash, itching, erythema) to drugs containing macrogol (polyethylene glycol). The medicinal product contains sulfur dioxide, which in rare cases can cause severe hypersensitivity reactions and bronchospasm. The drug should not be taken by patients with congenital fructose intolerance. In the event of diarrhea, special attention should be paid to patients prone to fluid and electrolyte imbalance (i.e. the elderly, patients with impaired liver and kidney function or patients taking diuretics), blood electrolyte levels should be monitored. Cases of aspiration have been reported with the introduction of large volumes of polyethylene glycol and electrolytes through a nasogastric tube. Children with neurological disorders and oral dysfunction are especially at risk of aspiration. Precautions when using Forlax does not contain sugar or polyol and can be prescribed to patients with diabetes mellitus or patients who are on a galactose-free diet. Interaction with other medicinal products Not applicable. If you are taking or have recently taken any other medicines, ask your doctor or pharmacist for advice. Application during pregnancy and lactation The effect of the drug on the ability to drive vehicles and work with moving mechanisms has not been established. Side effects Adverse reactions are listed by category and frequency of occurrence: very often (≥1/10); often (≥1/100 <1/10); infrequently (≥1/1000 <1/100); rarely (≥1/10000 <1/1000); very rarely (<1/10000); "not determined" - in cases where the frequency cannot be determined from the available data. Adults: The side effects listed below were identified during clinical trials (involving almost 600 patients) and during post-marketing surveillance. As a rule, the identified adverse reactions were minor, were temporary in nature and were mainly related to the digestive system: Gastrointestinal disorders Common: pain in the abdomen, bloating, diarrhea, nausea Uncommon: vomiting, urgency to defecate, fecal incontinence Immune system disorders Not determined: hypersensitivity reactions (anaphylactic shock, Quincke's edema, urticaria, rash, pruritus, erythema) Metabolic disorders Not determined: electrolyte imbalance (hyponatremia, hypokalemia) and / or dehydration, especially in elderly patients. Children The side effects presented below were identified during clinical trials that included 147 children aged 6 months to 15 years and during post-marketing surveillance. As in adults, adverse effects in the pediatric population were minor, transient, and related to the digestive system: Gastrointestinal disorders Common: Abdominal pain, diarrhea* Uncommon: Vomiting, bloating, nausea Side effects immune system Not determined: hypersensitivity reactions (anaphylactic shock, Quincke's edema, urticaria, rash, itching) * Diarrhea can cause pain in the perianal area. If you experience any unusual reactions, be sure to tell your doctor. OverdoseOverdose may cause diarrhea, abdominal pain and vomiting. Diarrhea caused by an overdose of the drug disappears with a temporary cessation of treatment or with a decrease in dosage. Excessive fluid loss due to diarrhea or vomiting may require correction of the electrolyte balance. Packing 10 g of powder in a bag (kraft paper/aluminum foil/polyethylene). 20 sachets in a carton box along with instructions for use. Storage conditionsKeep out of the reach of children. Does not require special storage conditions. Shelf life 3 years. Terms of dispensing from pharmaciesWithout a prescription. Buy Forlax powder for oral solution in sachets 10g №20 Price for Forlax powder for oral solution in sachets 10g No. 20